Research Progress of Trastuzumab in the Treatment of HER-2 Positive Breast Cancer
10.13241/j.cnki.pmb.2017.27.047
- VernacularTitle:曲妥珠单抗在HER-2阳性乳腺癌治疗中的研究进展
- Author:
Wenlong LIANG
;
Lin LIU
;
Xi CHEN
;
Bin SHEN
;
Jianguo ZHANG
- Keywords:
Breast cancer;
Human epidermal growth factor receptor-2,HER-2;
Trastuzumab
- From:Progress in Modern Biomedicine
2017;17(27):5385-5388
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is one of the most common malignancies happened in female patients.The incidence of breast cancer in Chinese females has increased in recently years.Human epidermal growth factor receptor-2 (HER-2) exhibits gene amplification or high expression of receptor protein in about one third of breast cancer patients.HER-2 positive breast cancer patients has poor prognosis,high risk of recurrence and short survival.Trastuzumab is a specific inhibitor of human epidermal growth factor receptor-2 [1],which has been widely used in the treatment of HER-2-positive breast cancer patients,and trastuzumab molecular targeting therapy compared with the traditional chemotherapy,with the advantages of high specificity and low toxicity.It changes the natural disease progression of patients with HER-2-positive breast cancer and prolongs the patient's survival time.This article will review the researches on the four aspects,which including the development and the application of trastuzumab in the treatment of HER-2 positive breast cancer.
